Login / Signup

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.

James D ChalmersPhilipp BadorrekClaudia DiefenbachHarald KöglerWiebke SauterStefan KreideweissJens M Hohlfeld
Published in: ERJ open research (2024)
Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.
Keyphrases